Last reviewed · How we verify
nebulized ketamine
Nebulized ketamine works by blocking NMDA receptors in the brain, which can help reduce inflammation and pain.
Nebulized ketamine works by blocking NMDA receptors in the brain, which can help reduce inflammation and pain. Used for Treatment-resistant depression, Chronic pain.
At a glance
| Generic name | nebulized ketamine |
|---|---|
| Also known as | Ketalar |
| Sponsor | Theresa Jacob, PhD, MPH |
| Drug class | anesthetic |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 3 |
Mechanism of action
By blocking NMDA receptors, nebulized ketamine can help reduce the release of pro-inflammatory chemicals and decrease pain perception. This can be particularly beneficial for patients with chronic pain or respiratory conditions. However, the exact mechanisms of action are still being studied.
Approved indications
- Treatment-resistant depression
- Chronic pain
Common side effects
- Dizziness
- Headache
- Nausea
Key clinical trials
- Comparison of Nebulized Ketamine With Nebulized Magnesium Sulfate for the Prevention of Postoperative Sore Throat (NA)
- Nebulized Sub-dissociative Dose Ketamine at Three Different Dosing Regimens for Treating Acute Pain in the Pediatric ED (PHASE4)
- Nebulized Dexmedetomidine Combined With Ketamine Versus Nebulized Dexmedetomidine for Cleft Palate (PHASE4)
- Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations (PHASE2)
- Comparing Nebulized Ketamine,Nebulized Ketamine and Precedex and IM Ketamine for Analgesia in Pediatric Burn (PHASE1)
- Nebulized vs. IV Ketamine in Preventing Shivering Post Spinal Anesthesia (NA)
- Pre-emptive Analgesia Using Nebulized Ketamine Versus Nebulized Dexmedetomidine in Endoscopic Nasal Surgeries (NA)
- Nebulized Ketamine to Nebulized Fentanyl for Treating Acute Painful Conditions in the ED (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nebulized ketamine CI brief — competitive landscape report
- nebulized ketamine updates RSS · CI watch RSS
- Theresa Jacob, PhD, MPH portfolio CI